Table 2.

Pharmacokinetic parameters of carbidopa after administering of placebo or entacapone 200 mg with different doses of l-dopa/carbidopa.

	Cmax (ng ml−1)		tmax (h)		AUC (0,12h) (ng ml−1 h)
l-dopa/carbidopa dose (mg)	Placebo	Entacapone	Placebo	Entacapone	Placebo	Entacapone
50/12.5	39 ± 23	40 ± 19	1.9 ± 1.0	2.1 ± 0.7	132 ± 92	121 ± 76
		(-0.22, 0.93)				(-0.37, 1.16)
100/10	31 ± 18	33 ± 15	2.3 ± 0.9	2.0 ± 0.6	95 ± 71	93 ± 66
		(-0.18, 0.91)				(-0.56, 0.97)
100/25	82 ± 33	76 ± 35	2.4 ± 0.9	2.8 ± 0.9	335 ± 147	313 ± 161
		(-0.63, 046)				(-0.87, 0.67)
150/37.5	113 ± 40	111 ± 39	2.3 ± 0.9	2.6 ± 0.9	484 ± 170	550 ± 226
		(-0.63, 0.56)				(-0.70, 0.88)
200/50	126 ± 45	132 ± 38	3.2 ± 1.0	2.9 ± 0.7	586 ± 243	670 ± 193
		(-0.41, 0.47)				(-0.49, 0.72)
250/25	54 ± 27	69 ± 25	3.2 ± 1.5	3.8 ± 1.1	229 ± 118	321 ± 151
		(-0.03, 0.85)				(-0.10, 1.11)

Values are means with s.d., n = 14–16; 95% confidence intervals on the differences between the mean values for entacapone vs placebo are given in parentheses. There were no statistically significant differences between entacapone and placebo. Statistical significance was concluded if the 95% confidence interval excluded 0.